![]() |
|
| |||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||
Medical Guidelines ReferencesGeneral1. Guidelines for Red Blood Cell and Plasma Transfusion for Adults and Children; Report of the Expert Working Group. CMAJ 1997 (Suppl); 156: 11: 51-524 2. Practice Strategies for Elective RBC Transfusion. American College of Physicians (1992), Annals of Internal Medicine 116: 5: 403-406 3. Prudent Strategies for Elective RBC Transfusion. Welch HG, et al. (1992), ibid 393 – 402 4. Perioperative RBC Transfusion. Consensus Conference (1988), JAMA, 260: 18: 2700 – 2703 5. Strategies for the Review of Transfusion Practices. Silborstein, et al. (1989) JAMA, 262: 14: 1993 – 1997 6. Practice Guidelines for Blood Component Therapy. American Society of Anesthesiologists Task Force. (1996), Anesthesiology 84: 732 – 47 7. Guidelines for the Use of FFP. Contreras M, et al. (1992) Transfusion Medicine, 2: 57 – 63 8. Guidelines for the Use of FFP, Cryoprecipitate and Cryosupernatant, BCSH Transfusion Task Force (2004) Brit J Haem, 126:11-28 9. Guidelines for Blood Utilization Review. Stehling L, et al, (1994), Transfusion 34: 5: 438 – 448 Platelets10. Guidelines for Platelet Transfusions. Murphy MF, et al. (1992), Transfusion Medicine, 2: 311 – 318 11. Consensus Conference on Platelet Transfusion. Royal College of Physicians of Edinburgh. (1995) Brit. J. Haem; 101: 609 – 617 Albumin12. Guidelines for Albumin Use in Adults in British Columbia. Provincial Blood Coordinating Office. October 2007. 13. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. The SAFE study investigators, (2004). N Engl J Med. 350(22): 2247-56. Plasma Volume Expanders14. Hydroxyethyl Starch Products Comparison Table. Canadian Blood Services. Customer Letter 2007-43. IVIG15. Evidence Based Guidelines for IVIG Use for Hematologic and Neurologic Conditions. Robison P, Anderson D et al (2007) Transfusion Medicine Reviews 21:2:Supp.1, 53-58. Infection16. A Comparison of Filtered Leukocyte – Reduced and CMV Seronegative Blood Products for the Prevention of Transfusion Associated CMV Infection After Marrow Transplant. Bowden RA, et al. (1995) Blood 86: 9: 3598 – 3603 17. Consensus Conference on Prevention of Post-Transfusion CMV in the Era of Leukoreduction. Laupacis, A et al. Transfusion (2001), 41 (4): 560-569. 18. Risk Associated with Transfusion of Cellular Blood Components in Canada. Kleinman S et al. Transfusion Medicine Reviews (2003) 17(2): 120 –162. 19. Physicians Guide 2001. Informed Consent for Blood and Blood Products. British Columbia Provincial Blood Coordinating Office. 20. Allogeneic Blood Transfusion, Immunodulation and Post-Operative Bacterial Infection, Blajchman MA, Editorial, Transfusion, (1997), 37:121 – 125 21. Incidence and Significance of the Bacterial Contamination of Blood Componenets. Blajchman MA. Development in Biologicals (2002). 108: 59-67. rF VIIa22. A critical appraisal of use of recombinant F VIIa in acquired bleeding disorders. Mittal S, Watson HG (2006) Brit J Haem 133, 355-362. | |||||||||||||||||||||||||||||||||||||||||
Page updated on Apr 24, 2008 at 4:58 PM. Please read our Legal Disclaimer. Copyright © 2003 Calgary Laboratory Services. All rights reserved. |
|||||||||||||||||||||||||||||||||||||||||